<DOC>
	<DOCNO>NCT00265226</DOCNO>
	<brief_summary>The purpose study study efficacy safety Mycobacterium treating patient lung tuberculosis . Mycobacterium strain bacterium use vaccine adjuvant drug leprosy . This agent also find effective treatment lung tuberculosis limit number patient . The researcher conduct study World Health Organization ( WHO ) category-II lung tuberculosis patient see efficacy also see change immunological parameter .</brief_summary>
	<brief_title>Efficacy Safety Study Immunomodulator Adjunct Therapy Pulmonary Tuberculosis ( TB ) Retreatment Patients</brief_title>
	<detailed_description>Mycobacterium w recently introduce immunomodulator , find useful rapid kill Mycobacterium leprae . It improve clearance Mycobacterium leprae body thereby useful reduce duration therapy significantly multibacillary leprosy . Mycobacterium w share antigen Mycobacterium leprae well Mycobacterium tuberculosis . Mycobacterium w also find useful prevention tuberculosis experimental animal . Previous study efficacy Mycobacterium w immunomodulator pulmonary tuberculosis patient show high sputum conversion rate patient give Mycobacterium w adjuvant therapy along standard anti-tuberculosis treatment . It faster remarkable sputum convert capacity . Similar study conduct pulmonary TB category -II [ re-treatment per Revised National Tuberculosis Control Programme ( RNTCP ) , Govt . India ] patient show improved cure rate . Mycobacterium w commercially available brand name `` Immuvac '' injection 0.5 ml multi dose vial approve use immunomodulator Mycobacterium leprae patient leprosy . Each vial 0.5 x 10^9 heat-killed bacillus buffer solution . It manufacture Cadila Pharmaceuticals Ltd. ; Ahmedabad , Gujarat-382 210 , India . In clinical trial one dose consist 0.1 ml give intradermal injection , contain 10^9 bacillus . A total 6 dos give Intensive Phase ( per RNTCP , Govt . India ) treatment . Two injection upper arm day-0 subsequently one injection day 14 , 28 , 42 56 . No injection give Continuation Phase ( per RNTCP , Govt . India ) treatment . As , commercially available use TB patient immunomodulator . Therefore , investigator investigate Mycobacterium w ( Mw ) efficacy TB patient `` double-blind placebo-controlled randomized clinical control trial '' fashion . We conduct trial Category-II pulmonary TB patient ( per RNTCP , Govt . India ) , assess outcome form clinical improvement , sputum conversion immunological parameter . This multi-centric trial sponsor Department Biotechnology , Ministry Science Technology , Govt . India Cadila Pharmaceuticals Ltd. , India .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Immunologic Factors</mesh_term>
	<mesh_term>Adjuvants , Immunologic</mesh_term>
	<criteria>Patients sputum positive pulmonary tuberculosis treat previously 1 month per RNTCP/WHO guideline . Category II inclusion mean patient Treatment Default/Treatment Failure/Treatment Relapse . Patients willing give write informed consent . Patients know hypersensitive ATTs administer . Patients coinfected HIV , hepatitis B hepatitis C. Pregnant lactate female female child bear age urine HCG positive result 2448 hour prior every injection Mw till 8 week . Patients abnormal renal function , liver function hematological test . Seriously ill moribund patient complication low lung reserve , mark tachypnoea , chronic cor pulmonale , congestive heart failure . Severely malnourished patient body mass index ( BMI ) &lt; 15 Severe hypoalbuminemia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>India</keyword>
	<keyword>Pulmonary Tuberculosis</keyword>
	<keyword>Category-II tuberculosis</keyword>
	<keyword>Immunomodulator</keyword>
	<keyword>Mycobacterium w</keyword>
	<keyword>Revised National Tuberculosis Control Programme</keyword>
	<keyword>Category-II Pulmonary Tuberculosis</keyword>
</DOC>